Cargando…
Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases
Free vaccination against COVID-19 commenced in India on January 16, 2021, and the government is urging all of its citizens to be immunized, in what is expected to be the largest vaccination program in the world. Out of the eight COVID-19 vaccines that are currently under various stages of clinical t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169891/ https://www.ncbi.nlm.nih.gov/pubmed/33883557 http://dx.doi.org/10.1038/s41541-021-00327-2 |
_version_ | 1783702118711951360 |
---|---|
author | Kumar, Velayudhan Mohan Pandi-Perumal, Seithikurippu R. Trakht, Ilya Thyagarajan, Sadras Panchatcharam |
author_facet | Kumar, Velayudhan Mohan Pandi-Perumal, Seithikurippu R. Trakht, Ilya Thyagarajan, Sadras Panchatcharam |
author_sort | Kumar, Velayudhan Mohan |
collection | PubMed |
description | Free vaccination against COVID-19 commenced in India on January 16, 2021, and the government is urging all of its citizens to be immunized, in what is expected to be the largest vaccination program in the world. Out of the eight COVID-19 vaccines that are currently under various stages of clinical trials in India, four were developed in the country. India’s drug regulator has approved restricted emergency use of Covishield (the name employed in India for the Oxford-AstraZeneca vaccine) and Covaxin, the home-grown vaccine produced by Bharat Biotech. Indian manufacturers have stated that they have the capacity to meet the country’s future needs for COVID-19 vaccines. The manpower and cold-chain infrastructure established before the pandemic are sufficient for the initial vaccination of 30 million healthcare workers. The Indian government has taken urgent measures to expand the country’s vaccine manufacturing capacity and has also developed an efficient digital system to address and monitor all the aspects of vaccine administration. |
format | Online Article Text |
id | pubmed-8169891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-81698912021-06-07 Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases Kumar, Velayudhan Mohan Pandi-Perumal, Seithikurippu R. Trakht, Ilya Thyagarajan, Sadras Panchatcharam NPJ Vaccines Perspective Free vaccination against COVID-19 commenced in India on January 16, 2021, and the government is urging all of its citizens to be immunized, in what is expected to be the largest vaccination program in the world. Out of the eight COVID-19 vaccines that are currently under various stages of clinical trials in India, four were developed in the country. India’s drug regulator has approved restricted emergency use of Covishield (the name employed in India for the Oxford-AstraZeneca vaccine) and Covaxin, the home-grown vaccine produced by Bharat Biotech. Indian manufacturers have stated that they have the capacity to meet the country’s future needs for COVID-19 vaccines. The manpower and cold-chain infrastructure established before the pandemic are sufficient for the initial vaccination of 30 million healthcare workers. The Indian government has taken urgent measures to expand the country’s vaccine manufacturing capacity and has also developed an efficient digital system to address and monitor all the aspects of vaccine administration. Nature Publishing Group UK 2021-04-21 /pmc/articles/PMC8169891/ /pubmed/33883557 http://dx.doi.org/10.1038/s41541-021-00327-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Perspective Kumar, Velayudhan Mohan Pandi-Perumal, Seithikurippu R. Trakht, Ilya Thyagarajan, Sadras Panchatcharam Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases |
title | Strategy for COVID-19 vaccination in India: the country with the
second highest population and number of cases |
title_full | Strategy for COVID-19 vaccination in India: the country with the
second highest population and number of cases |
title_fullStr | Strategy for COVID-19 vaccination in India: the country with the
second highest population and number of cases |
title_full_unstemmed | Strategy for COVID-19 vaccination in India: the country with the
second highest population and number of cases |
title_short | Strategy for COVID-19 vaccination in India: the country with the
second highest population and number of cases |
title_sort | strategy for covid-19 vaccination in india: the country with the
second highest population and number of cases |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169891/ https://www.ncbi.nlm.nih.gov/pubmed/33883557 http://dx.doi.org/10.1038/s41541-021-00327-2 |
work_keys_str_mv | AT kumarvelayudhanmohan strategyforcovid19vaccinationinindiathecountrywiththesecondhighestpopulationandnumberofcases AT pandiperumalseithikurippur strategyforcovid19vaccinationinindiathecountrywiththesecondhighestpopulationandnumberofcases AT trakhtilya strategyforcovid19vaccinationinindiathecountrywiththesecondhighestpopulationandnumberofcases AT thyagarajansadraspanchatcharam strategyforcovid19vaccinationinindiathecountrywiththesecondhighestpopulationandnumberofcases |